BySara Dorn,
Forbes Staff.
Eli Lilly and Novo Nordisk will cut prices of their obesity drugs and Medicare will begin covering the drugs for some patients beginning next year, pursuant to a deal President Donald Trump announced Thursday with the drug companies.
Treatments will be offered directly to consumers on a new “TrumpRx.gov” website launching in January, including new obesity pills from Eli Lilly and Novo Nordisk, which will also be available to Medicare and Medicaid recipients.
The companies will cut the price Medicare pays for the GLP-1s—which cost about $1,000 to $1,350 per month before insurance—to $245 per month, and offer all 50 states the lower price for Medicaid programs.
